AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25363127 — intervention group
Group type: COMPARATOR
Intervention: saline (control group) with lidocaine 2%
Number of subjects: 48
Study 22538029 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational LMA insertion technique
Number of subjects: 100
Study 22538029 — intervention group
Group type: COMPARATOR
Intervention: Standard LMA insertion technique
Number of subjects: 100
Study 22538029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study 20375984 — intervention group
Group type: EXPERIMENTAL
Intervention: SBR759 at 11.25 g/day
Number of subjects: 44
Study 20375984 — intervention group
Group type: EXPERIMENTAL
Intervention: SBR759 at 15.0 g/day
Number of subjects: 44
Study 20375984 — intervention group
Group type: EXPERIMENTAL
Intervention: SBR759 at 3.75-15 g/day
Number of subjects: 44
Study 20375984 — intervention group
Group type: EXPERIMENTAL
Intervention: SBR759
Number of subjects: 44
Study 18599797 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg with medroxyprogesterone acetate 2.5 mg daily
Number of subjects: 16747
Study 18599797 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg daily
Number of subjects: 16747
Study 18599797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16747
Study 16377296 — intervention group
Group type: EXPERIMENTAL
Intervention: sitaxsentan
Number of subjects: 178
Study 16377296 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 178
Study 12887173 — intervention group
Group type: EXPERIMENTAL
Intervention: Duac Topical Gel (clindamycin 1%‐benzoyl peroxide 5%)
Number of subjects: 358
Study 10958817 — intervention group
Group type: COMPARATOR
Intervention: Step‐1 diet (29% fat, 9% SFA)
Number of subjects: 27
Study 10958817 — intervention group
Group type: COMPARATOR
Intervention: Low‐Sat diet (25% fat, 6% SFA)
Number of subjects: 27
Study 8790035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (4-week training period)
Number of subjects: 256
Study 8790035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 256
Study 8790035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 256
Study 1299794 — intervention group
Group type: EXPERIMENTAL
Intervention: delta sleep-inducing peptide (DSIP) 25 nmol/kg body weight
Number of subjects: 16
Study 1299794 — intervention group
Group type: COMPARATOR
Intervention: glucose solution (placebo)
Number of subjects: 16
Study 6830203 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 272
Study 6830203 — intervention group
Group type: COMPARATOR
Intervention: Control (no furosemide)
Number of subjects: 272
Study 30811685 — intervention group
Group type: EXPERIMENTAL
Intervention: High postural sway (highest quartile of ML sway)
Number of subjects: 1568
Study 30811685 — intervention group
Group type: EXPERIMENTAL
Intervention: High postural sway (fourth quartile of ML sway)
Number of subjects: 1568
Study 30811685 — intervention group
Group type: EXPERIMENTAL
Intervention: High postural sway (highest quartile of total sway)
Number of subjects: 1568
Study 30811685 — intervention group
Group type: EXPERIMENTAL
Intervention: High postural sway (fourth quartile of total sway)
Number of subjects: 1568
Study 30811685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lowest bone density and highest postural sway
Number of subjects: 1568
Study 30811685 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural sway
Number of subjects: 1568
Study 29332749 — intervention group
Group type: EXPERIMENTAL
Intervention: Direction-movement control training for 30 min/day, three days per week for six months
Number of subjects: 30
Study 29332749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 26628416 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT (1.1 × 10(6)/kg UC‐MSC, 106.8 × 10(6)/kg aBM‐MNC)
Number of subjects: 42
Study 26628416 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 42
Study 23643327 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 166
Study 23643327 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 166
Study 22763575 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT)
Number of subjects: 158
Study 20498056 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 24
Study 20498056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18274221 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructivist curriculum (experimental group)
Number of subjects: 76
Study 18274221 — intervention group
Group type: COMPARATOR
Intervention: Nonconstructivist curriculum (comparison group)
Number of subjects: 76
Study 16287357 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load squat (HS)
Number of subjects: 15
Study 16287357 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded countermovement jump (LCMJ)
Number of subjects: 15
Study 16287357 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study 11972478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nangai (Canarium indicum)
Number of subjects: 12
Study 11972478 — intervention group
Group type: COMPARATOR
Intervention: Double blind placebo controlled food challenge (DBPCFC)
Number of subjects: 12
Study 11972478 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine release (HR) test
Number of subjects: 12
Study 11972478 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 12
Study 10533949 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical audit intervention group
Number of subjects: 133
Study 10533949 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study 8697726 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly group with iron deficiency anaemia
Number of subjects: 0
Study 8697726 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged adults with iron deficiency anaemia
Number of subjects: 0
Study 8697726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (elderly and middle-aged adults)
Number of subjects: 0
Study 2316409 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape instruction
Number of subjects: 540
Study 2316409 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape instruction plus peer leader involvement
Number of subjects: 540
Study 2316409 — intervention group
Group type: COMPARATOR
Intervention: Survey-only
Number of subjects: 540
Study 2316409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure resistance training without peer leader involvement
Number of subjects: 540
Study 2316409 — intervention group
Group type: EXPERIMENTAL
Intervention: Social resistance training with peer leader involvement
Number of subjects: 540
Study 7000857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate in 1% lidocaine
Number of subjects: 12
Study 7000857 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole nafate in saline
Number of subjects: 12
Study 7000857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate (both diluents)
Number of subjects: 12
Study 31721467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day for 24 weeks
Number of subjects: 54
Study 31721467 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 30712364 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for high-risk CAD defined as left main stenosis (≥50% stenosis)
Number of subjects: 4589
Study 30712364 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for high-risk CAD defined as ≥70% stenosis of 3 vessels or 2-vessel CAD involving the proximal left anterior descending artery
Number of subjects: 4589
Study 30712364 — intervention group
Group type: COMPARATOR
Intervention: Models compared to Pooled Cohort Equation
Number of subjects: 4589
Study 30712364 — intervention group
Group type: COMPARATOR
Intervention: Models compared to Diamond-Forrester risk scores
Number of subjects: 4589
Study 30712364 — intervention group
Group type: COMPARATOR
Intervention: High-risk CAD vs non-high-risk CAD
Number of subjects: 4589
Study 28460889 — intervention group
Group type: EXPERIMENTAL
Intervention: Olesoxime (10 mg/kg per day)
Number of subjects: 165
Study 28460889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 28460889 — intervention group
Group type: EXPERIMENTAL
Intervention: Olesoxime
Number of subjects: 165
Study 26507206 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS (Levonorgestrel-releasing intrauterine system)
Number of subjects: 571
Study 26507206 — intervention group
Group type: COMPARATOR
Intervention: Usual medical treatment (tranexamic acid, mefenamic acid, combined oestrogen-progestogen or progesterone alone)
Number of subjects: 571
Study 26507206 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 571
Study 26507206 — intervention group
Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 571
Study 24037893 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with TPF regimen (docetaxel 75 mg/m(2), cisplatin 75 mg/m(2), and 5‐fluorouracil 2500 mg/m(2) every 3 weeks for 3 cycles) followed by concurrent chemoradiation (cisplatin 40 mg/m(2) per week with either 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy)
Number of subjects: 116
Study 21326600 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus macaque monkey
Number of subjects: 1
Study 21326600 — intervention group
Group type: COMPARATOR
Intervention: Human subjects
Number of subjects: 1
Study 19517892 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (amisulpride 200 mg)
Number of subjects: 12
Study 19517892 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (amisulpride 200 mg)
Number of subjects: 12
Study 19517892 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 12
Study 17361206 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced membranous Ep-CAM staining at the invasive margin
Number of subjects: 133
Study 14648244 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene mesh
Number of subjects: 600
Study 14648244 — intervention group
Group type: COMPARATOR
Intervention: Vypro II mesh
Number of subjects: 600
Study 11447776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular administration of high molecular weight sodium hyaluronate (one 20 mg vial/week for 3 weeks)
Number of subjects: 30
Study 15512177 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg daily
Number of subjects: 18
Study 15512177 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate 10 mg daily
Number of subjects: 18
Study 7517472 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with vasoactive compounds
Number of subjects: 0
Study 7517472 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term physical exercise (twice for 2 h/week for 24 months)
Number of subjects: 0
Study 7517472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapeutic regimens using intravenous infusions
Number of subjects: 0
Study 7517472 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 0
Study 2538252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) with CDDP and vindesine
Number of subjects: 61
Study 2538252 — intervention group
Group type: COMPARATOR
Intervention: Cis‐dichlorodiammineplatinum (CDDP) and vindesine without STS
Number of subjects: 61
Study 31254797 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Training (FUNCT)
Number of subjects: 47
Study 31254797 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Training (TRAD)
Number of subjects: 47
Study 31254797 — intervention group
Group type: COMPARATOR
Intervention: Stretching Group (STRETCH)
Number of subjects: 47
Study 28114646 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program‐Tinnitus (BFP‐T) completed online 1 hour per day, 5 days per week for 8 weeks
Number of subjects: 40
Study 28114646 — intervention group
Group type: COMPARATOR
Intervention: Non-BFP‐T control group
Number of subjects: 40
Study 28114646 — intervention group
Group type: EXPERIMENTAL
Intervention: BFP‐T group
Number of subjects: 40
Study 28114646 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 40
Study 23871729 — intervention group
Group type: EXPERIMENTAL
Intervention: G biloba
Number of subjects: 102
Study 23871729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 21715510 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (4 hours/night)
Number of subjects: 30
Study 21715510 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (9 hours/night)
Number of subjects: 30
Study 19452696 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and levofloxacin for 2 weeks followed by levofloxacin only for another 2 weeks
Number of subjects: 160
Study 19452696 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin and placebo for 2 weeks followed by placebo only for another 2 weeks
Number of subjects: 160
Study 19452696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups evaluated for WBC count in EPS
Number of subjects: 160
Study 16933577 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (Group 1)
Number of subjects: 48
Study 16933577 — intervention group
Group type: COMPARATOR
Intervention: Hyperlipidemia without statin (Group 2)
Number of subjects: 48
Study 16933577 — intervention group
Group type: COMPARATOR
Intervention: Normal cholesterol level controls (Group 3)
Number of subjects: 48
Study 15152589 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural preemptive analgesia with 2 micrograms/kg fentanyl in 0.25% bupivacaine in 10 ml serum saline
Number of subjects: 60
Study 15152589 — intervention group
Group type: COMPARATOR
Intervention: Control group received 10 ml serum saline 20 minutes before the incision
Number of subjects: 60
Study 11310460 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular midazolam (0.4 mg/kg)
Number of subjects: 87
Study 11310460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal flumazenil (25 microg/kg)
Number of subjects: 87
Study 11310460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intramuscular ketamine (2.5 mg/kg)
Number of subjects: 87
Study 9135272 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic oral rehydration solution (ORS)
Number of subjects: 0
Study 9135272 — intervention group
Group type: COMPARATOR
Intervention: Isotonic high glucose ORS
Number of subjects: 0
Study 8361875 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 18
Study 8361875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3691913 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil (3% solution)
Number of subjects: 90
Study 3691913 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil (5% solution)
Number of subjects: 90
Study 3691913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30307958 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week multicomponent intervention (social norm, informational/educational, appeal to fear, mind attribution induction, goal setting/self-monitoring)
Number of subjects: 32
Study 30307958 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week multicomponent intervention
Number of subjects: 32
Study 30307958 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational component of the intervention
Number of subjects: 32
Study 27322089 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Delivery App (SDA)
Number of subjects: 3601
Study 27322089 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 3601
Study 24825597 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft (HT)
Number of subjects: 96
Study 24825597 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft (PT)
Number of subjects: 96
Study 22098056 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture adhesive
Number of subjects: 30
Study 22098056 — intervention group
Group type: COMPARATOR
Intervention: No denture adhesive (Control)
Number of subjects: 30
Study 21901950 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 60
Study 21901950 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobupivacaine
Number of subjects: 60
Study 21901950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 19552097 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500mg orally 8 hourly daily for initial 3 months, followed by clomiphene 50mg orally once daily for 5 days for subsequent 3 months
Number of subjects: 27
Study 19552097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (folic acid 5mg orally once daily for initial 3 months), followed by clomiphene 50mg orally once daily for 5 days for subsequent 3 months
Number of subjects: 27
Study 16181919 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced sternal closure with three stainless steel double wires
Number of subjects: 100
Study 16181919 — intervention group
Group type: COMPARATOR
Intervention: Standard techniques with stainless steel single wires
Number of subjects: 100
Study 12418791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 10 units/kg
Number of subjects: 125
Study 12418791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 20 units/kg
Number of subjects: 125
Study 12418791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 30 units/kg
Number of subjects: 125
Study 12418791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 11148694 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoscreening method for detecting vision problems
Number of subjects: 0
Study 11148694 — intervention group
Group type: EXPERIMENTAL
Intervention: Microchips and heat sensors for compliance with amblyopia therapy
Number of subjects: 0
Study 11148694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic and penalization rehabilitation methods
Number of subjects: 0
Study 11148694 — intervention group
Group type: COMPARATOR
Intervention: Vision screening in children
Number of subjects: 0
Study 9350166 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate beer consumption (330 ml of Maccabee beer, > 20 g of alcohol) for 30 consecutive days
Number of subjects: 48
Study 9350166 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption (control group)
Number of subjects: 48
Study 8476405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 0
Study 8476405 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 8476405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill placebo
Number of subjects: 0
Study 8476405 — intervention group
Group type: COMPARATOR
Intervention: Matched control words
Number of subjects: 0
Study 8476405 — intervention group
Group type: EXPERIMENTAL
Intervention: Color words
Number of subjects: 0
Study 8476405 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically threatening words
Number of subjects: 0
Study 3545354 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 3545354 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 31615726 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpreserved trehalose 3%, hyaluronic acid 0.15%, carbomer 0.25% (THHA, Thealoz Duo Gel)
Number of subjects: 122
Study 31615726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.3% (HA)
Number of subjects: 122
Study 31615726 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 122
Study 30285758 — intervention group
Group type: EXPERIMENTAL
Intervention: internet delivered cognitive behaviour therapy (iCBT) plus treatment as usual (TAU)
Number of subjects: 0
Study 30285758 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 0
Study 27180023 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.04 mg/kg) and propofol (1.0 μg/mL)
Number of subjects: 38
Study 27180023 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1.5 μg/mL)
Number of subjects: 38
Study 27180023 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and propofol
Number of subjects: 38
Study 27180023 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 38
Study 24630053 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 287
Study 24630053 — intervention group
Group type: COMPARATOR
Intervention: Randomized treatment assignment
Number of subjects: 287
Study 24630053 — intervention group
Group type: COMPARATOR
Intervention: Randomized trial participation
Number of subjects: 287
Study 22287534 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured information plus values clarification exercises
Number of subjects: 156
Study 22287534 — intervention group
Group type: COMPARATOR
Intervention: Only structured information
Number of subjects: 156
Study 20724140 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU, folinic acid and cisplatin combination followed by gemcitabine (Arm A)
Number of subjects: 202
Study 20724140 — intervention group
Group type: COMPARATOR
Intervention: Opposite sequence (Arm B)
Number of subjects: 202
Study 20724140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (Arm A and Arm B)
Number of subjects: 202
Study 18541264 — intervention group
Group type: EXPERIMENTAL
Intervention: TissueLink (saline-linked radiofrequency dissecting sealer)
Number of subjects: 122
Study 18541264 — intervention group
Group type: COMPARATOR
Intervention: Crushing clamp
Number of subjects: 122
Study 16167420 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin/benzoyl peroxide gel (combination formulation)
Number of subjects: 0
Study 16167420 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin/benzoyl peroxide gel + tretinoin gel + clindamycin gel
Number of subjects: 0
Study 16167420 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin/benzoyl peroxide gel
Number of subjects: 0